BSX · Earnings call · 2026Q3T · Full report

Products and Technology

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 37 · Surprise 40

Neuromodulation grew 13%, led in pain by Nalu PNS and in brain by the Cartesia X lead and Illumina 3D software; management also cited positive three-month real-world outcomes for Intracept in the IMPROVE study. Urology’s new stone products include Navigator FLEX, 7.5 Fr SlimScope, and LithoVue Elite, while endoscopy’s Axios technology continued to lead its underlying performance. In cardiovascular, Agent DCB had treated more than 400,000 patients, and SEISMIC IVL gained clearance for small-vessel disease and expanded use above and below the knee; the 3.5 drug-coated balloon adds a complementary treatment option. Management also highlighted future launches including a new SCS platform, CRM’s Denali defibrillator platform, EP’s 2D ICE and FARAWAVE Ultra, and WATCHMAN FLX Pro.

Key facts

• Boston Scientific received FDA clearance for SEISMIC IVL to treat severely calcified peripheral artery disease in small vessels, extending treatment above and below the knee.
• Boston Scientific received FDA approval for its 3.5 drug-coated balloon, expanding available size options.
• Agent DCB has been used to treat over 400,000 patients to date.